New triple therapy aims to reverse early type 2 diabetes
NCT ID NCT07635953
First seen Jun 13, 2026 · Last updated Jun 16, 2026 · Updated 1 time
Summary
This study tests whether a combination of three drugs (tirzepatide, empagliflozin, and pioglitazone) can help people newly diagnosed with type 2 diabetes achieve remission better than standard metformin-based therapy. About 296 adults will take the triple combo or standard treatment daily for 6 months, then stop medication to see if their blood sugar stays normal. The goal is to improve beta-cell function and achieve diabetes remission without needing lifelong drugs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, 510080, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.